|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000516 |
Purpose
To determine if enalapril treatment of left ventricular dysfunction (LVD) due to ischemic or hypertensive heart disease led to reduced mortality and morbidity in symptomatic and asymptomatic patients. There were a Prevention Trial, a Treatment Trial, and a registry.
| Condition | Intervention | Phase |
|---|---|---|
|
Cardiovascular Diseases Coronary Disease Heart Diseases Heart Failure Hypertension Myocardial Ischemia |
Drug: enalapril |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Masking: Double-Blind Primary Purpose: Prevention |
Eligibility| Ages Eligible for Study: | 21 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Men and women, ages 21 to 80. Subjects were asymptomatic or symptomatic and had ejection fractions equal to or below 35 percent.
Contacts and Locations
More Information
| ClinicalTrials.gov Identifier: | NCT00000516 History of Changes |
| Other Study ID Numbers: | 35 |
| Study First Received: | October 27, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Federal Government |
|
Cardiovascular Diseases Myocardial Ischemia Coronary Artery Disease Coronary Disease Heart Diseases Heart Failure Hypertension Ischemia Ventricular Dysfunction, Left Ventricular Dysfunction Vascular Diseases Arteriosclerosis |
Arterial Occlusive Diseases Pathologic Processes Enalapril Angiotensin-Converting Enzyme Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antihypertensive Agents Cardiovascular Agents Therapeutic Uses |